Search
Bailiantianheng's Licensed-in Revenue Hits US$800 Million, Turning Around to Profitability
2025-01-21 /
Read about 0 minute
Author：小编
Bailiantianheng is poised to generate a revenue of RMB 58 billion in 2025, marking a remarkable year-over-year surge of 932.27%, alongside a net profit of approximately RMB 3.6 billion, signifying a transition into profitability. This significant growth is primarily fueled by an overseas collaboration agreement for its core product BL-B01D1, which has secured an upfront payment of US$800 million from Bristol-Myers Squibb. The clinical development of BL-B01D1 is progressing steadily, with multiple Phase III studies already underway, encompassing a broad spectrum of cancer types.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
